Black Diamond Therapeutics
Filed with the SEC on · accession 0001701541-26-000032
BDTX filed a 10-Q (quarterly report) with the SEC on Nov 10, 2026. The quarterly report: unaudited results for the quarter plus management’s comments.
Black Diamond Therapeutics filed its Q3 2026 Form 10-Q, reporting routine quarterly financial results and disclosures for the period ended September 30, 2026.
✦ Ask GOAX AI about this filing — what it means for BDTX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for BDTX?
Click hereBDTX filed a 10-Q (SEC filing). Black Diamond Therapeutics filed its Q3 2026 Form 10-Q, reporting routine quarterly financial results and disclosures for the period ended September 30, 2026.
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
Get alerts when BDTX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days